• Research Paper on:
    Analysis of Wyeth Lederle's Prevnar Production

    Number of Pages: 10

     

    Summary of the research paper:

    In ten pages this paper discusses the process of this vaccine and what is required for FDA approval. Seven sources are cited in the bibliography with the inclusion of two illustrations.

    Name of Research Paper File: MM12_PGprvnr.rtf

    Buy This Research Paper »

     

    Unformatted Sample Text from the Research Paper:
    a couple of illustrations but given the examples, it should be easy for the student to fill in with the other graphics.] Product Life Cycle and Market Demand Prevnar is  one of the latest releases from Wyeth Lederle; it is a Pneumococcal Conjugate Vaccine (PCV-7) (CDC, 2001). This vaccine has been shown to be effective in preventing invasive pneumococcal disease  in small children (CDC, 2001). Prior to Wyeths development and release of Prevnar, "pneumococcal infections caused approximately 700 cases of meningitis, 17,000 cases of bacteremia - blood stream infections -  and 200 deaths each year in children under age five" (CDC, 2001). The most severe infection this drug prevents is meningitis (CDC, 2001). Approximately five percent of children under the  age of 5 years who contract pneumococcal meningitis will die of this disease (CDC, 2001). Wyeth, formerly named American Home Products (Wyeth, 2002). is a leader in the research and  development of numerous types of health care and medical care products (Wyeth, 2002). The major divisions within the company include: Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health  (Wyeth, 2002). Through its different divisions, the company is involved in discovering, developing, manufacturing and marketing pharmaceuticals, vaccines, biotechnology products and non-prescription medicines (Wyeth, 2002). This paper focuses on Prevnar,  which is in the vaccine division. Wyeth manufactures other vaccines, including: * FluShield(r), Influenza Virus Vaccine, which helps to prevent getting influenza; * Pnu-Imune(r) 23, Pneumococcal Vaccine, which helps  to prevent pneumococcal diseases in adults, such as pneumonia, * HibTITER(r), Haemophilus b Conjugate Vaccine, which helps to prevent Haemophilus influenzae type b, also known as Hib disease, including  meningitis, in children (Wyeth, nd). The Market Portfolio is presented in the following illustration. Demand Forecast The model used and brief explanations for the products in the 

    Back to Research Paper Results